1. 2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo. (September 2015) Authors: Petrylak, D.; Eigl, B.; Senkus, E.; Loriot, Y.; Twardowski, P.; Castellano, D.; Blais, N.; Sridhar, S.; Sternberg, C.; Retz, M.; Blumenstein, B.; Jacobs, C.; Stewart, P.; Bellmunt, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). (5th December 2016) Authors: Cardoso, F.; Costa, A.; Senkus, E.; Aapro, M.; André, F.; Barrios, C. H.; Bergh, J.; Bhattacharyya, G.; Biganzoli, L.; Cardoso, M. J.; Carey, L.; Corneliussen-James, D.; Curigliano, G.; Dieras, V.; El Saghir, N.; Eniu, A.; Fallowfield, L.; Fenech, D.; Francis, P.; Gelmon, K. Journal: Annals of oncology Issue: Volume 28:Number 1(2017) Page Start: 16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). (February 2017) Authors: Cardoso, F.; Costa, A.; Senkus, E.; Aapro, M.; André, F.; Barrios, C.H.; Bergh, J.; Bhattacharyya, G.; Biganzoli, L.; Cardoso, M.J.; Carey, L.; Corneliussen-James, D.; Curigliano, G.; Dieras, V.; El Saghir, N.; Eniu, A.; Fallowfield, L.; Fenech, D.; Francis, P.; Gelmon, K. Journal: Breast Issue: Volume 31(2017) Page Start: 244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). (February 2017) Authors: Cardoso, F.; Costa, A.; Senkus, E.; Aapro, M.; André, F.; Barrios, C.H.; Bergh, J.; Bhattacharyya, G.; Biganzoli, L.; Cardoso, M.J.; Carey, L.; Corneliussen-James, D.; Curigliano, G.; Dieras, V.; El Saghir, N.; Eniu, A.; Fallowfield, L.; Fenech, D.; Francis, P.; Gelmon, K. Journal: Breast Issue: Volume 31(2017) Page Start: 244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AA2 Overtreatment in early breast cancer – who is at risk?. (April 2023) Authors: Senkus, E. Journal: Breast Issue: Volume 68(2023)Supplement Page Start: S13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). (April 2017) Authors: Duffy, M.J.; Harbeck, N.; Nap, M.; Molina, R.; Nicolini, A.; Senkus, E.; Cardoso, F. Journal: European journal of cancer Issue: Volume 75(2017) Page Start: 284 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244–259]. (April 2017) Authors: Cardoso, F.; Costa, A.; Senkus, E.; Aapro, M.; André, F.; Barrios, C.H.; Bergh, J.; Bhattacharyya, G.; Biganzoli, L.; Cardoso, M.J.; Carey, L.; Corneliussen-James, D.; Curigliano, G.; Dieras, V.; El Saghir, N.; Eniu, A.; Fallowfield, L.; Fenech, D.; Francis, P.; Gelmon, K. Journal: Breast Issue: Volume 32(2017) Page Start: 269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Magnitude of clinical benefit: anything different in young women?. (October 2018) Authors: Senkus, E. Journal: Breast Issue: Volume 41(2018)Supplement 1 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes. (April 2023) Authors: Johnston, S.; Toi, M.; O'Shaughnessy, J.; Rastogi, P.; Campone, M.; Neven, P.; Huang, C.S.; Huober, J.; Jaliffe, G. Garnica; Cicin, I.; Tolaney, S.; Goetz, M.P.; Rugo, H.; Senkus, E.; Testa, L.; Del Mastro, L.; Shimizu, C.; Wei, R.; Shahir, A.; Munoz, M. Journal: Breast Issue: Volume 68(2023) Page Start: S22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (25th August 2015) Authors: Senkus, E.; Kyriakides, S.; Ohno, S.; Penault-Llorca, F.; Poortmans, P.; Rutgers, E.; Zackrisson, S.; Cardoso, F. Journal: Annals of oncology Issue: Volume 26(2015)Supplement 5 Page Start: v8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗